Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.50 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulosemide SCHEMBL30704848 | 0.99 | ALDH1A1 (0.51) | ALDH1A1CA12CA1CA2HTR1A | |
| Sulosemide SCHEMBL1818931 | 0.99 | ALDH1A1 (0.51) | ALDH1A1CA12CA1CA2HTR1A | |
| SCHEMBL11555324 | 0.90 | ALDH1A1 (0.51) | ALDH1A1CA12CA1CA2HTR1A | |
| SCHEMBL11555977 | 0.90 | ALDH1A1 (0.46) | ALDH1A1CA12CA1CA2HTR1A | |
| SCHEMBL11554161 | 0.90 | ALDH1A1 (0.46) | ALDH1A1CA12CA1CA2HTR1A | |
| SCHEMBL11551926 | 0.89 | CA12 (0.50) | ALDH1A1CA12CA1CA2HTR1A | |
| SCHEMBL10966537 | 0.89 | ALDH1A1 (0.42) | ALDH1A1CA12CA1CA2HTR1A | |
| SCHEMBL11554544 | 0.88 | ALDH1A1 (0.45) | ALDH1A1CA12CA1CA2HTR1A | |
| SCHEMBL11550929 | 0.88 | ALDH1A1 (0.45) | ALDH1A1CA12CA1CA2HTR1A | |
| Sulosemide SCHEMBL10965264 | 0.88 | ALDH1A1 (0.48) | ALDH1A1CA12CA1CA2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140024683-A1 | CHLORIDE CHANNEL AND CHLORIDE TRANSPORTER MODULATORS FOR THERAPY IN SMOOTH MUSCLE DISEASES | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2014-01-23 | — | — | US | claimed |
| WO-2012134965-A1 | CHLORIDE CHANNEL AND CHLORIDE TRANSPORTER MODULATORS FOR THERAPY IN SMOOTH MUSCLE DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-10-04 | — | — | WO | claimed |
| US-20140024683-A1 | CHLORIDE CHANNEL AND CHLORIDE TRANSPORTER MODULATORS FOR THERAPY IN SMOOTH MUSCLE DISEASES | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2014-01-23 | — | — | US | disclosed |
| WO-2012134965-A1 | CHLORIDE CHANNEL AND CHLORIDE TRANSPORTER MODULATORS FOR THERAPY IN SMOOTH MUSCLE DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024683-A1 | CHLORIDE CHANNEL AND CHLORIDE TRANSPORTER MODULATORS FOR THERAPY IN SMOOTH MUSCLE DISEASES | CLCN2, SLC6A1, SLC26A3 | ALDH1A1 2189/4885CA12 2608/4885CA1 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.